HCV Treatment
EASL 2015: Sofosbuvir/ Ledipasvir + Ribavirin Cures Most Hepatitis C Patients with Advanced Liver Disease
- Details
- Category: HCV Treatment
- Published on Thursday, 23 April 2015 00:00
- Written by Liz Highleyman
An oral regimen of sofosbuvir/ledipasvir (Harvoni) and ribavirin taken for 12 or 24 weeks produced sustained virological response rates of 85%-88% for genotype 1 hepatitis C patients with decompensated cirrhosis and 95%-98% for liver transplant recipients with less advanced liver damage, according to preliminary results from the SOLAR-2 study presented at the European Association for the Study of the Liver (EASL) 50th International Liver Congress taking place this week in Vienna.
EASL 2015: Merck Hepatitis C Combination Achieves 90% Cure in Advanced Cirrhosis Patients
- Details
- Category: Experimental HCV Drugs
- Published on Thursday, 23 April 2015 00:00
- Written by Keith Alcorn
A 12-week course of treatment with 2 direct-acting antivirals in development by Merck cured hepatitis C virus infection in 90% of people with very advanced cirrhosis and at imminent risk of liver failure, Ira Jacobson of Weill Cornell Medical College reported at the European Association for the Study of the Liver (EASL) 50th International Liver Congress this week in Vienna. The Phase 2 study looked at the use of the HCV protease inhibitor grazoprevir and the NS5A inhibitor elbasvir in people with Child-Pugh B cirrhosis.
EASL 2015: International Liver Congress Now Underway in Vienna
- Details
- Category: HCV Treatment
- Published on Wednesday, 22 April 2015 00:00
- Written by HIVandHepatitis.com
The European Association for the Study of the Liver's International Liver Congress (EASL 2015) takes place April 22-26 at the Reed Messe Wien Centre in Vienna, Austria. The annual meeting -- one of the key scientific conferences covering hepatitis B and C and its complications -- is observing its 50th year. Look for breaking news coverage from HIVandHepatitis.com and our partners at Aidsmap.com starting Friday at www.HIVandHepatitis.com and via @HIVandHepatitis on Twitter. Abstracts and other information are available on the International Liver Congress website.
EASL 2015: Merck HCV Combination Effective after Failure of First Generation Direct-Acting Antivirals
- Details
- Category: Experimental HCV Drugs
- Published on Thursday, 23 April 2015 00:00
- Written by Keith Alcorn
Treatment for 12 weeks with grazoprevir and elbasvir, 2 direct-acting antivirals being development by Merck, plus ribavirin, cured 95% of people with hepatitis C who had experienced failure of a previous combination containing an HCV protease inhibitor, Xavier Forns of the University of Barcelona Hospital Clinic reported the at the European Association for the Study of the Liver (EASL) 50th International Liver Congress this week in Vienna.
ASCEND Study Looks at Community-based Hepatitis C Treatment
- Details
- Category: Approved HCV Drugs
- Published on Wednesday, 22 April 2015 00:00
- Written by Liz Highleyman
A new trial sponsored by the U.S. National Institutes of Health will evaluate whether primary care physicians and other health care providers such as nurse practitioners can provide interferon-free therapy for hepatitis C as effectively as hepatologists or infectious disease specialists. If successful, community-based care could greatly expand the number of people able to access treatment.
More Articles...
- Allergy Drug Inhibits Hepatitis C Virus Replication in Mouse Study
- Janssen Interferon-Free Regimen with Simeprevir Cures Most Patients with Genotype 1 HCV
- CROI 2015: Good Sofosbuvir/Ledipasvir Adherence in SYNERGY and ERADICATE Trials
- FDA Warns of Heart Risk When Combining Amiodarone with Sovaldi or Harvoni
Web Design and Development by